Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2550
Peer-review started: August 31, 2021
First decision: November 17, 2021
Revised: November 18, 2021
Accepted: January 27, 2022
Article in press: January 27, 2022
Published online: March 16, 2022
Vancomycin remains a first-line treatment drug as per the treatment guidelines for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. However, a number of gram-positive cocci have developed resistance to several drugs, including glycopeptides. Therefore, there is an urgent need for effective and innovative antibacterial drugs to treat patients with infections caused by drug-resistant bacteria.
A 24-year-old male was admitted to hospital owing to lumbago, fever, and hematuria. Computed tomography (CT) results showed an abscess in the psoas major muscle of the patient. Repeated abscess drainage and blood culture suggested MRSA, and vancomycin was initiated. However, after day 10, CT scans showed abscesses in the lungs and legs of the patient. Therefore, treatment was switched to daptomycin. Linezolid was also added considering inflammation in the lungs. After 10 d of the dual-drug anti-MRSA treatment, culture of the abscess drainage turned negative for MRSA. On day 28, the patient was discharged without any complications.
This case indicates that daptomycin combined with linezolid is an effective remedy for bacteremia caused by MRSA with pulmonary complications.
Core Tip: We analyzed a case of severe methicillin-resistant Staphylococcus aureus (MRSA) bacteremia who failed to respond to first line treatment using vancomycin. We believe that our study makes a significant contribution to the literature because it indicates that daptomycin combined with linezolid is an effective remedy for bacteremia caused by MRSA with pulmonary complications.